Glaukos Co. (NYSE:GKOS) Shares Sold by Segall Bryant & Hamill LLC

Segall Bryant & Hamill LLC reduced its stake in Glaukos Co. (NYSE:GKOS) by 3.9% in the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 105,956 shares of the medical instruments supplier’s stock after selling 4,327 shares during the period. Segall Bryant & Hamill LLC’s holdings in Glaukos were worth $13,804,000 as of its most recent SEC filing.

Other institutional investors also recently made changes to their positions in the company. Values First Advisors Inc. acquired a new position in Glaukos during the 3rd quarter valued at about $25,000. GAMMA Investing LLC raised its holdings in shares of Glaukos by 68.8% during the second quarter. GAMMA Investing LLC now owns 1,192 shares of the medical instruments supplier’s stock valued at $141,000 after buying an additional 486 shares during the last quarter. Fifth Third Wealth Advisors LLC acquired a new position in shares of Glaukos during the second quarter worth approximately $187,000. KBC Group NV grew its holdings in Glaukos by 16.2% in the 3rd quarter. KBC Group NV now owns 1,445 shares of the medical instruments supplier’s stock worth $188,000 after buying an additional 201 shares in the last quarter. Finally, Brighton Jones LLC acquired a new stake in Glaukos in the 2nd quarter valued at approximately $208,000. 99.04% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

A number of research analysts have issued reports on the company. BTIG Research boosted their price target on Glaukos from $131.00 to $139.00 and gave the stock a “buy” rating in a research report on Wednesday, August 28th. Needham & Company LLC boosted their price target on shares of Glaukos from $131.00 to $137.00 and gave the stock a “buy” rating in a research report on Thursday, August 1st. Stifel Nicolaus lifted their price objective on shares of Glaukos from $130.00 to $145.00 and gave the stock a “buy” rating in a research note on Tuesday, September 3rd. Truist Financial upped their price target on Glaukos from $145.00 to $152.00 and gave the company a “buy” rating in a report on Monday, October 14th. Finally, JPMorgan Chase & Co. lifted their target price on Glaukos from $130.00 to $145.00 and gave the stock an “overweight” rating in a report on Tuesday, November 5th. Four investment analysts have rated the stock with a hold rating and eight have given a buy rating to the company. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $134.55.

Insider Activity at Glaukos

In other Glaukos news, COO Joseph E. Gilliam sold 2,275 shares of the firm’s stock in a transaction that occurred on Wednesday, October 30th. The stock was sold at an average price of $138.97, for a total value of $316,156.75. Following the sale, the chief operating officer now owns 102,169 shares of the company’s stock, valued at $14,198,425.93. This trade represents a 2.18 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, Director Gilbert H. Kliman sold 3,000 shares of the company’s stock in a transaction that occurred on Monday, September 9th. The stock was sold at an average price of $130.67, for a total value of $392,010.00. Following the transaction, the director now owns 32,336 shares of the company’s stock, valued at approximately $4,225,345.12. This trade represents a 8.49 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 6.40% of the stock is owned by company insiders.

Glaukos Trading Down 1.9 %

Shares of NYSE:GKOS opened at $141.44 on Thursday. The firm has a fifty day moving average of $131.75 and a two-hundred day moving average of $123.18. The company has a quick ratio of 4.71, a current ratio of 5.54 and a debt-to-equity ratio of 0.19. Glaukos Co. has a 12-month low of $59.22 and a 12-month high of $145.84. The firm has a market capitalization of $7.80 billion, a P/E ratio of -46.83 and a beta of 1.02.

Glaukos (NYSE:GKOS) last posted its earnings results on Monday, November 4th. The medical instruments supplier reported ($0.28) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.48) by $0.20. Glaukos had a negative net margin of 42.43% and a negative return on equity of 18.99%. The firm had revenue of $96.70 million during the quarter, compared to analysts’ expectations of $91.50 million. During the same period in the previous year, the company earned ($0.50) earnings per share. The company’s revenue was up 23.9% compared to the same quarter last year. On average, equities analysts expect that Glaukos Co. will post -1.96 EPS for the current fiscal year.

About Glaukos

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma.